Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Patients with cystic fibrosis and advanced lung disease benefit from lumacaftor/ivacaftor treatment

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Pulmonary diffusing capacity measured by NO/CO transfer in Tunisian boys

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Lung compartment analysis assessed from N2 multiple-breath washout in children with cystic fibrosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Cystic fibrosis newborn screening in Denmark: Experience from the first 2 years

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. The impact of mannose-binding lectin polymorphisms on lung function in primary ciliary dyskinesia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Omics-based tracking of Pseudomonas aeruginosa persistence in "eradicated" cystic fibrosis patients.

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Bacterial persisters in long-term infection: Emergence and fitness in a complex host environment

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Lung clearance index-triggered intervention in children with cystic fibrosis - A randomised pilot study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Pseudomonas aeruginosa antibody response in cystic fibrosis decreases rapidly following lung transplantation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND: Several studies have assessed safety and efficacy outcomes for lumacaftor/ivacaftor therapy. We report on lumacaftor/ivacaftor's impact on lung function, physical performance, and health-related quality of life (HRQOL) in a subpopulation of Danish people with Cystic Fibrosis (CF; PWCF) with advanced pulmonary disease who would not fulfill inclusion criteria for these studies.

METHODS: This follow-up study examined lumacaftor/ivacaftor's effect in a highly selected CF population. Inclusion criteria included low percent predicted forced expiratory volume in one second (ppFEV1 ), fast deteriorating ppFEV1 , low body mass index (BMI), and difficult-to-treat infections. Primary endpoints included change in ppFEV1 slope, cardiopulmonary exercise testing (CPET), and all domains of the Cystic Fibrosis Questionnaire-Revised (CFQ-R). Secondary outcomes included change in ppFEV1 , BMI Z-score, and sweat chloride concentration.

RESULTS: A total of 21 patients homozygous for the F508del mutation and a median ppFEV1 of 38.7 were included. We found significant improvements in ppFEV1 (+4.2 p < .01, +5.8 p < .01, +4.8 p < .01 and +3.8 p = .03 ppFEV1 after 3, 6, 9, and 12 months of treatment compared to baseline), ppFEV1 slope (+6.84 ppFEV1 /year between the year before and the year after treatment initiation; p = .02), and saturation at CPET initiation (+1.4%, p < .02) and termination (+2.6%, p < .01) after 6 months of treatment. Finally, HRQOL improved significantly in all CFQ-R domains except Emotion and Treat.

CONCLUSIONS: Our findings suggest that lumacaftor/ivacaftor reduces lung function decline, improves lung function, physical performance, and HRQOL to a greater extent in PWCF with severe lung disease than previously recognized.

OriginalsprogEngelsk
TidsskriftPediatric Pulmonology
Vol/bind55
Udgave nummer12
Sider (fra-til)3364-3370
Antal sider7
ISSN8755-6863
DOI
StatusUdgivet - dec. 2020

Bibliografisk note

© 2020 Wiley Periodicals LLC.

ID: 62370186